Pictet Asset Management Holding SA Has $11.08 Million Position in West Pharmaceutical Services, Inc. $WST

Pictet Asset Management Holding SA cut its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 70.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,190 shares of the medical instruments supplier’s stock after selling 107,807 shares during the quarter. Pictet Asset Management Holding SA’s holdings in West Pharmaceutical Services were worth $11,076,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC increased its stake in West Pharmaceutical Services by 8.9% in the first quarter. Venturi Wealth Management LLC now owns 2,773 shares of the medical instruments supplier’s stock valued at $695,000 after purchasing an additional 227 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in West Pharmaceutical Services in the first quarter worth $927,000. Fifth Third Wealth Advisors LLC bought a new position in shares of West Pharmaceutical Services during the first quarter worth $231,000. OP Asset Management Ltd bought a new position in shares of West Pharmaceutical Services during the first quarter worth $1,870,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $88,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of West Pharmaceutical Services stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Up 0.0%

Shares of WST stock opened at $365.87 on Friday. West Pharmaceutical Services, Inc. has a 12-month low of $206.80 and a 12-month high of $367.66. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. The firm has a fifty day moving average of $322.63 and a 200-day moving average of $278.87. The company has a market capitalization of $25.85 billion, a price-to-earnings ratio of 48.91, a P/E/G ratio of 3.06 and a beta of 1.16.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, beating the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.67 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on WST. Wolfe Research began coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. KeyCorp lifted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Finally, Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services has an average rating of “Buy” and an average price target of $343.73.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.